S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)

Acrivon Therapeutics (ACRV) Stock Price, News & Analysis

$4.92
-0.06 (-1.20%)
(As of 12/29/2023 ET)
Today's Range
$4.89
$5.05
50-Day Range
$3.63
$5.75
52-Week Range
$3.41
$25.47
Volume
22,098 shs
Average Volume
38,807 shs
Market Capitalization
$109.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.50

Acrivon Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
377.6% Upside
$23.50 Price Target
Short Interest
Bearish
2.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.63) to ($2.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

642nd out of 950 stocks

Pharmaceutical Preparations Industry

311th out of 442 stocks


ACRV stock logo

About Acrivon Therapeutics Stock (NASDAQ:ACRV)

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

ACRV Stock Price History

ACRV Stock News Headlines

MarketBeat All Access New Year's Sale - Just $1.00
Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.
Analyst Ratings for Acrivon Therapeutics
MarketBeat All Access New Year's Sale - Just $1.00
Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.
Recap: Acrivon Therapeutics Q3 Earnings
Analyst Expectations for Acrivon Therapeutics's Future
See More Headlines
Receive ACRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/31/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/26/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRV
Fax
N/A
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.50
High Stock Price Target
$26.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+377.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-31,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.16 per share

Miscellaneous

Free Float
20,574,000
Market Cap
$109.19 million
Optionable
Not Optionable
Beta
N/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Peter Blume-Jensen M.D. (Age 60)
    Ph.D., Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer
    Comp: $1.01M
  • Ms. Kristina Masson M.B.A. (Age 42)
    Ph.D., Co-Founder, Executive VP of Business Operations, Site Head, Treasurer, Secretary & Director
  • Mr. Rasmus Holm-Jorgensen (Age 52)
    Chief Financial Officer
    Comp: $1M
  • Dr. Eric J. Devroe Ph.D. (Age 45)
    Chief Operating Officer
    Comp: $614.78k
  • Ms. Katharine Peterson CPA
    Vice President of Finance & Accounting
  • Dr. Adam D. Levy M.B.A.
    Ph.D., Senior VP and Head of Investor Relations & Corporate Affairs
  • Mr. Bruce Close
    Vice President of Quality & Compliance
  • Ms. Mary-Alice Miller J.D. (Age 49)
    General Counsel
  • Ms. Parvin Miah
    VP & Head of Human Resources
  • Dr. Erick Gamelin M.D. (Age 65)
    Ph.D., Chief Medical Officer
    Comp: $480.72k














ACRV Stock Analysis - Frequently Asked Questions

Should I buy or sell Acrivon Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acrivon Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACRV shares.
View ACRV analyst ratings
or view top-rated stocks.

What is Acrivon Therapeutics' stock price target for 2024?

6 brokers have issued 12 month price targets for Acrivon Therapeutics' stock. Their ACRV share price targets range from $20.00 to $26.00. On average, they predict the company's stock price to reach $23.50 in the next year. This suggests a possible upside of 377.6% from the stock's current price.
View analysts price targets for ACRV
or view top-rated stocks among Wall Street analysts.

How have ACRV shares performed in 2023?

Acrivon Therapeutics' stock was trading at $11.52 on January 1st, 2023. Since then, ACRV stock has decreased by 57.3% and is now trading at $4.92.
View the best growth stocks for 2023 here
.

When is Acrivon Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024.
View our ACRV earnings forecast
.

How were Acrivon Therapeutics' earnings last quarter?

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) posted its earnings results on Thursday, November, 9th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.06.

What ETF holds Acrivon Therapeutics' stock ?

Range Cancer Therapeutics ETF holds 10,409 shares of ACRV stock, representing 1.23% of its portfolio.

When did Acrivon Therapeutics IPO?

(ACRV) raised $100 million in an initial public offering (IPO) on Tuesday, November 15th 2022. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO.

How do I buy shares of Acrivon Therapeutics?

Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACRV) was last updated on 12/31/2023 by MarketBeat.com Staff

My Account -